This is a Phase III, randomized, open-label, multicenter, global study designed to compare the efficacy and safety of BGB-A317 versus Sorafenib as a first-line systemic treatment in patients with Unresectable Hepatocellular Carcinoma.
Principal Investigator: Suma Satti, MD
|Full Protocol Title||BGB-A317-301: A Randomized, Open-label, Multicenter Phase III Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (RATIONALE-301)|
Baton Rouge Clinic
|Change in Care||Participating may change your care|